Zhejiang NHU Past Earnings Performance
Past criteria checks 2/6
Zhejiang NHU has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 17% per year. Zhejiang NHU's return on equity is 11.2%, and it has net margins of 18%.
Key information
6.8%
Earnings growth rate
6.6%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 17.0% |
Return on equity | 11.2% |
Net Margin | 18.0% |
Next Earnings Update | 23 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zhejiang NHU makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 15,036 | 2,710 | 720 | 890 |
30 Jun 23 | 15,137 | 2,890 | 647 | 835 |
31 Mar 23 | 15,238 | 3,060 | 622 | 821 |
31 Dec 22 | 15,934 | 3,620 | 622 | 859 |
30 Sep 22 | 16,213 | 3,975 | 580 | 863 |
30 Jun 22 | 15,792 | 4,143 | 584 | 871 |
31 Mar 22 | 15,435 | 4,415 | 591 | 851 |
01 Jan 22 | 14,917 | 4,356 | 581 | 783 |
30 Sep 21 | 13,455 | 4,020 | 609 | 716 |
30 Jun 21 | 12,351 | 3,782 | 642 | 678 |
31 Mar 21 | 11,480 | 3,808 | 722 | 612 |
31 Dec 20 | 10,314 | 3,564 | 731 | 546 |
30 Sep 20 | 9,338 | 3,398 | 731 | 491 |
30 Jun 20 | 9,074 | 3,221 | 710 | 462 |
31 Mar 20 | 8,449 | 2,554 | 651 | 434 |
31 Dec 19 | 7,660 | 2,165 | 630 | 435 |
30 Sep 19 | 7,760 | 2,244 | 570 | 438 |
30 Jun 19 | 7,921 | 2,173 | 599 | 432 |
31 Mar 19 | 7,474 | 2,096 | 597 | 450 |
31 Dec 18 | 8,683 | 3,079 | 599 | 457 |
30 Sep 18 | 8,862 | 3,341 | 620 | 433 |
30 Jun 18 | 8,278 | 3,177 | 438 | 553 |
31 Mar 18 | 8,053 | 2,966 | 477 | 438 |
31 Dec 17 | 6,235 | 1,704 | 515 | 336 |
30 Sep 17 | 5,366 | 1,258 | 518 | 215 |
30 Jun 17 | 5,002 | 1,273 | 685 | 0 |
31 Mar 17 | 4,838 | 1,279 | 652 | 0 |
31 Dec 16 | 4,696 | 1,203 | 624 | 0 |
30 Sep 16 | 4,414 | 962 | 582 | 0 |
30 Jun 16 | 4,194 | 732 | 576 | 0 |
31 Mar 16 | 3,951 | 477 | 559 | 0 |
31 Dec 15 | 3,823 | 402 | 548 | 0 |
30 Sep 15 | 3,965 | 380 | 573 | 0 |
30 Jun 15 | 3,965 | 445 | 561 | 0 |
31 Mar 15 | 4,158 | 685 | 539 | 0 |
31 Dec 14 | 4,164 | 808 | 522 | 0 |
30 Sep 14 | 4,390 | 984 | 518 | 0 |
30 Jun 14 | 4,350 | 1,020 | 498 | 0 |
31 Mar 14 | 4,181 | 896 | 463 | 0 |
31 Dec 13 | 4,238 | 882 | 440 | 0 |
30 Sep 13 | 3,785 | 700 | 364 | 0 |
30 Jun 13 | 3,775 | 732 | 362 | 0 |
31 Mar 13 | 3,704 | 777 | 372 | 0 |
Quality Earnings: 002001 has high quality earnings.
Growing Profit Margin: 002001's current net profit margins (18%) are lower than last year (24.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002001's earnings have grown by 6.8% per year over the past 5 years.
Accelerating Growth: 002001's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002001 had negative earnings growth (-31.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.5%).
Return on Equity
High ROE: 002001's Return on Equity (11.2%) is considered low.